REPLICor to disclose new mechanism of action data and interim REP 9AC and REP 9AC’ clinical efficacy data in patients with chronic hepatitis B at the 2011 HEPDART meeting.
December 4-8, 2011, Grand Hyatt Kauai, Koloa, Hawaii
Montreal, Quebec – Friday, November 25, 2011 – REPLICor will disclose new mechanism of action data and updated interim results from its two proof of concept clinical trials with REP 9AC and REP 9AC’ at the 2011 HEPDART meeting to be held from December 4th-8th, 2011. This exclusive meeting is only held every two years and convenes the top experts, opinion leaders and industry analysts. This meeting focuses on advancements in the development of drugs for the treatment of Hepatitis B and Hepatitis C.
REP 9AC and REP 9AC’ represent a new class of antiviral agent (nucleic acid polymers or NAPs) that block the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects contributes to the long term persistence of HBV infection in the liver. REP 9AC and REP 9AC’ rapidly clear HBsAg in the serum of patients infected with HBV and appears to allow these patients to regain effective immunological control over their infection, resulting in sustained virologic responses after only 5-6 months of treatment. REPLICor will present updated clinical efficacy results in a poster presentation running from December 5th-8th.
For the 2011 HEPDART meeting see: http://www.informedhorizons.com/hepdart2011/
Nov 4-8, 2011, Moscone Convention Center West, San Francisco USA 十一月4日至8日,2011年,Moscone West会议中心,旧金山美国
Montreal, Quebec – Friday, Oct 27, 2011 – REPLICor will disclose updated interim results from its proof of concept clinical trial at the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD 2011) to be held Nov 4-8, 2011. 蒙特利尔,魁北克-周五10月27日,2011 -将披露REPLICor更新从它的概念的临床试验证明在第62届美国协会年会上的肝病(AASLD 2011年)为11月四日至8日举行的中期业绩研究,2011年。 This is the largest annual meeting dedicated to treatment of liver disease which typically attracts thousands of physicians and researchers. 这是最大的年度会议专门治疗肝病哪个医生和研究人员通常吸引力数千人。 This trial is examining the safety and efficacy of REP 9AC in human patients with chronic hepatitis B (HBV). 这项试验是检查的REP 9AC安全,并与慢性乙型肝炎(HBV)人类患者的疗效。
REP 9AC represents a new class of antiviral agent that blocks the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects and may contribute to the long term persistence of HBV infection in the liver. REP 9AC代表新的抗病毒药剂类,阻止乙肝表面抗原(HBsAg),其中有过气与HBV特异性免疫缺陷和可能有助于HBV感染长期在肝内持久释放。 REP 9AC has been previously shown to rapidly clear HBsAg in the serum of patients infected with HBV and appears to allow these patients to regain effective immunological control over their infection, resulting in sustained virologic responses after only 5-6 months of treatment. REP 9AC过气先前表明,迅速 清除了乙肝病毒感染患者血清HBsAg和出现,使患者恢复到论文在他们的感染免疫有效控制,在持续病毒学反应所造成的治疗后,只有5-6个月。 REPLICor will present updated clinical efficacy results in an oral presentation on Tuesday Nov 8, 2011. 请问REPLICor目前周二2011年11月8号更新的口头报告年临床疗效结果。
For the 62nd meeting of the American Association for the Study of Liver Diseases see: http://www.aasld.org/lm2011/Pages/default.aspx 对于美国协会肝病研究第62次会议看到: http://www.aasld.org/lm2011/Pages/default.aspx